Niederhuber J E, Ensminger W, Gyves J W, Liepman M, Doan K, Cozzi E
Surgery. 1982 Oct;92(4):706-12.
A totally implanted venous and arterial access system was tested in 30 cancer patients. The device, an injection port (Infuse-A-Port, Infusaid Corp., Sharon, Mass.), consisted of a 3.5 by 1.5 cm conical chamber with a self-sealing silicone rubber septum connected to a Silastic catheter. Ten patents had the injection port operatively placed for arterial access. A total of 39 bolus injections and 18 continuous infusions lasting an average 5.4 +/- 3.4 days were administered through the port. The total time of arterial access ranged from 70 to 370 days. No special program of heparinization was required to maintain patency. The injection port was used for central venous access in 20 patients. The first six patients had a small lumen catheter of 0.38 mm internal diameter, and five had occlusion between 142 and 447 days. Subsequently, 19 ports with a larger catheter lumen of 0.63 mm were used. These ports functioned for an average of 274 +/- 110 days (23 to 382 days). There were 380 single bolus injections and 64 continuous infusions. A variety of anticancer agents as well as whole blood, blood products, and antibiotics were administered with the device without difficulty. Patient acceptance was excellent.
一种完全植入式动静脉通路系统在30例癌症患者中进行了测试。该装置为一个注射端口（Infuse - A - Port，Infusaid公司，马萨诸塞州沙龙市），由一个3.5×1.5厘米的锥形腔室组成，带有一个自密封硅橡胶隔膜，并连接到一根硅橡胶导管。10例患者通过手术将注射端口放置用于动脉通路。通过该端口共进行了39次推注注射和18次持续输注，平均持续时间为5.4±3.4天。动脉通路的总时间为70至370天。维持通畅无需特殊的肝素化方案。20例患者将注射端口用于中心静脉通路。前6例患者使用的是内径为0.38毫米的小腔导管，其中5例在142至447天之间出现堵塞。随后，使用了19个导管腔较大（内径为0.63毫米）的端口。这些端口平均使用了274±110天（23至382天）。共进行了380次单次推注注射和64次持续输注。使用该装置顺利输注了多种抗癌药物以及全血、血液制品和抗生素。患者的接受度良好。
